Director, Global Health Economics & Outcomes Research; HEOR

Company Overview

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.

At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more , and follow us on X, Linked In and Facebook.

We are seeking a Director, Global HEOR, to lead the strategy and execution of how we define, substantiate, and communicate the value of one or more medicines approaching commercialization. This role is responsible for ensuring that, from clinical development through real‑world evidence generation and payer engagement, we are making the strongest and best‑supported arguments to secure access to our medicines. Accordingly, the Director, Global HEOR, helps shape development plans, evidence strategies, and value narratives so that they align with how payers and health technology assessment (HTA) bodies make decisions, balancing analytical rigor with a clear focus on what is relevant for decision‑making.

This is a highly cross‑functional, hands‑on role for someone who combines deep analytical thinking with sound judgment, intellectual curiosity with pragmatism, and a strong orientation toward results. The role directly influences how our medicines are developed, positioned, and ultimately accessed by patients worldwide. Success in this role requires continually asking not just “Is this analysis methodologically defensible?” but “Does this help us make a better case for access, and if not, what would?”

This role is based in Waltham, MA.

• Informing development strategies from HEOR / market access perspective
• Represent the HEOR and market access perspective in internal clinical development and regulatory forums
• Provide critical input into clinical development plans, including protocol design, endpoint selection, and other aspects of clinical trial evidence generation, to ensure alignment with future payer and HTA expectations
• Communication of value to payers and HTA bodies
• Lead development of AMCP dossiers for US payers
• Lead development of cost‑effectiveness models for NICE and other HTA bodies requiring formal cost‑effectiveness analyses
• Serve as a core team member for HTA submissions outside the US, with responsibility for shaping and stress‑testing value narratives included in pricing and reimbursement dossiers and interpreting and recommending evidence to support such narratives, in a way that optimizes both credibility and relevance for payer decision‑making
• Make substantial contributions to other payer communication materials (e.g., Medical Value Liaison slide decks) and launch readiness activities as needed
• Leading real‑world evidence strategy and execution of real‑world analyses
• Lead planning of real‑world evidence generation activities to address evidence gaps as needed for informing decision‑making by payers, HTA bodies, and clinicians
• Oversee execution of real‑world data analyses, ensuring analytical rigor and fitness for purpose
• Interpret and translate results from real‑world analyses into peer‑reviewed publications and other external communications intended to meaningfully inform clinical practice and payer/HTA decision‑making

• Bachelor’s degree or equivalent experience in a relevant field such as economics, public health, epidemiology, biostatistics, health policy, life sciences, or a related discipline.
• Advanced degrees (Master’s, PhD, Pharm
  
  D, MD) are welcome but not required.
• 10+ years of progressive experience in HEOR, health analytics, value demonstration, market access, or a closely related quantitative or scientific field.
• Demonstrated success leading complex evidence‑generation, modeling, or analytical programs within biopharma, healthcare consulting, payer organizations, or academic…